• PN: B115602

COMPONENTS

45x Ab-conjugated beads (S5P12 - Human CA50 ab-bead). PN: B115602A. One vial containing 100 µL of anti-human CA50 conjugated to AimPlex Bead S5P12.

25x Biotin-detection Ab (Human CA50 Biotin-dAb). PN: B115602B. One vial containing 100 µL of biotinylated anti-human CA50.

Lyophilized Standard Mix - Human CA50. PN: B115602S. One vial containing lyophilized CA50.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human CA50. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 0.5 Unit/mL

Quantitation range:

LLOQ: < 1 Unit/mL

ULOQ: > 500 Unit/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Sample volume: 15 µL/test

Description:

Cancer Antigen 50 (CA50 or CA-50) are proteins mainly found in gastrointestinal cancers (e.g. pancreatic, stomach, hepatic and colorectal cancers) but also sometimes in other malignant growths (endometrial cancers). The CA-50 antigens occur in the cell membrane in a lipid-bound form (as ganglioside) and in a form bound to a high molecular weight protein (as glycoprotein). The CA-50 antigens are released by the tumors into the blood stream.

References:

1. Bunworasate U1, Voravud N. “CA 50: a tumor marker for gastrointestinal malignancies.” J Med Assoc Thai. 1995 May;78(5):255-70.

2. Haglund C1, Roberts PJ, Jalanko H, Kuusela P. “Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.” Scand J Gastroenterol. 1992;27(3):169- 74.

3. Persson BE1, Ståhle E, Påhlman L, Glimelius B, Holmgren J. “CA-50 as a tumour marker for monitoring colorectal cancer: antigen rises in patients postoperatively precede clinical manifestations of recurrence.” Eur J Cancer Clin Oncol. 1988 Feb;24(2):241-6.